"The tools of the trade" - An overview of the pharmacology of the endocannabinoid system

Current Pharmaceutical Design

Volumn 14, Issue 23, 2008, Pages 2254-2265

  Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

2 arachidonoylglycerol; Anandamide; Cannabinoid recoptor; Diacylglycerol lipase; Fatty acid amide hydrolase; Monoacylglycerol lipase

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 [2 ( 4 MORPHOLINYL)ETHYL] 1H INDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AMIDOHYDROLASE INHIBITOR; ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; GW 405833; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RIMONABANT; TARANABANT; UNCLASSIFIED DRUG; URB 602; VANILLOID RECEPTOR 1;

DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERANCE; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REVIEW; RNA INTERFERENCE; TACHYPHYLAXIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARACHIDONIC ACIDS; DRUG DELIVERY SYSTEMS; DRUG INVERSE AGONISM; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RNA INTERFERENCE;

EID: 52949149368     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785740126     Document Type: Review

References (195)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
3. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
4. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
5. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
6. Drew GM, Mitchell VA, Vaughan CW. Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling. J Neurosci 2008; 28: 808-15.
7. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 2004; 7: 697-8.
8. Wahn H, Wolf J, Kram F, Frantz S, Wagner JA. The endocannabinoid arachidonoyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 2005; 289: H2491-6.
9. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism land action. Br J Pharmacol 2007; 152: 594-601.
10. Woodward DF, Liang Y, Krauss A H-P. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 2008; 153: 410-9.
11. Alexander SPH, Kendall DA. The complications of promiscuity: endocannabinoid actio and metabolism. Br J Pharmacol 2007; 152: 602-23.
12. Mackie K. From active ingredients to the discovery of the targets: the cannabinoid receptors. Chem Biodivers 2007; 4: 1693-706.
13. Okamoto Y, Wang J, Morishita J, Ueda, N. Biosynthetic pahways of the endocannnabinoid anandamide. Chem Biodivers 2007; 4: 1842-57.
14. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45: 405-46.
15. Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol 2007; 101: 287-93.
16. Hanuš L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med. Chem 1993; 36: 3032-4.
17. Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterisation of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4.
18. Hanuš L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
19. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152:567-75.
20. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
21. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347-56.
22. Liu J, Wang L, Harvey-White J, Huang BX, Kim H-Y, Luquet S, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008; 54: 1-7.
23. Ben-Shabat S, Fride E, Slieskin T, Tamiri, T, Rhee M-H, Vogel Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonyl-glycerol cannabinoid activity. Eur J Pharmacol 1998; 353: 23-31.
24. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008; 11: 152-9.
25. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 2007; 152: 583-93.
26. Petitet F, Jeantaud B, Bertrand P, Imperato A. Cannabinoid penetration into mouse brain as determined by ex vivo binding. Eur J Pharmacol 1999; 374: 417-21.
27. 9-tetrahydrocannabinol, the main active, compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21: 6475-9.
28. 3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002; 137: 589-96.
29. 9-Tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 2006; 69: 991-7.
30. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73.
31. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80: 448-56.
32. Bloom AS, Edgemond WS, Moldvan JC. Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochem Res 1997; 22: 563-8.
33. Jordt S-E, Bautista DM, Chuang H-h, McKemy DD, Zygmunt PM, Högestätt ED, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004; 427: 260-5.
34. Bonhaus DW, Chang LK, Kwan J, Martin GR. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 1998; 287: 884-8.
35. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 2005; 315, 828-38.
36. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007; 150: 519-25.
37. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-95.
38. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155-63.
39. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNF in rat microglial cells stimulated with lypopolysaccharide. Glia 2003; 41: 161-8.
40. Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al. Cannabinoid activation of PPAR; a novel neuroprotective mechanism. Br J Pharmacol 2007; 152: 734-43.
41. 1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 2008; 54: 51-7.
42. Martínez-Orgado J, Fernández-Frutos B, González R, Romero E, Urigüen L, Romero J, et al. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Mol Brain Res 2003; 114: 132-9.
43. 2 receptor. Br J Pharmacol 2005; 145: 636-45.
44. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. Br J Pharmacol 2004; 142: 257-66.
45. 1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 2007; 101: 389-96 .
46. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002; 96: 253-60.
47. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 1999; 289:1427-33.
48. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004; 141: 1118-30.
49. 1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain. Pharmacol Rep 2006; 58: 870-5.
50. 1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004; 142: 1361-7.
51. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 1998; 41: 5353-61.
52. 1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 2005; 67: 2016-24.
53. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, et al. Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex. Cereb Cortex 2008; 18: 1292-301.
54. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129: 227-30.
55. Veale EL, Buswell R, Clarke CE, Mathie A. Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide. Br J Pharmacol 2007; 152: 778-86.
56. Roberts LA, Ross HR, Connor M. Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro. Neuropharmacology 2008; 54: 172-80.
57. Ramer R, Brune K, Pahl A, Hinz B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 2001; 286: 1144-52.
58. 4 muscarinic acetylcholine receptors. Brain Res 2001; 915: 70-8.
59. Offertáler L, Mo FM, Bátkai S, Liu J, Begg M, Razdan RK, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003; 63: 699-705.
60. 2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007; 321: 930-7.
61. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278: 989-99.
62. 2 cannabinoid receptors. Eur J Pharmacol 2004; 505: 1-9.
63. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006; 18: 949-56.
64. Duncan M, Kendall DA, Ralevic V. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. J Pharmacol Exp Ther 2004; 311: 411-9.
65. 2 receptor. Bioorg Med Chem 1999; 7: 2905-14.
66. 2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-8.
67. Wagner JA, Abesser M, Karcher J, Laser M, Kunos G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 2005; 46: 348-55.
68. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 2007; 151: 1061-70. Corrigendum in: Br J Pharmacol 2007; 151: 1137.
69. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 2006;149:145-54.
70. 2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003; 119: 747-57.
71. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008; 28: 1064-75.
72. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96: 14228-33.
73. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005; 48: 658-72.
74. 2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 2008; 153: 390-401.
75. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153: 319-34.
76. 1 cannabinoid receptor antagonists. Curr Opin Drug Discov Dev 2004; 7: 498-506.
77. Addy C, Wright H, Van Lacre K, Gantz I, Erondu N, Musser BJ, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7: 68-78.
78. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998; 284:291-7.
79. 1 cannabinoid receptors. Proc Natl Acad Sci USA 2007; 104: 20588-93.
80. Blais PA, Côté J, Morin J, Larouche A, Gendron G, Fortier A, et al. Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice. A comparative study. Peptides 2005; 26: 1317-22.
81. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 1999; 126: 665-72.
82. Chen J-Z, Wang J, Xie X-Q. GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model 2007; 47: 1626-37.
83. 1 receptors. Life Sci 2005; 76: 1307-24.
84. 1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in fats. Neuropsychopharmacology 2008; 33: 946-55.
85. Luk T, Jin W, Zvonok A, Lu D, Lin X-Z, Chavkin C, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004; 142: 495-500.
86. 1 receptors: the shape of things to come. Trends Pharmacol Sci 2007; 28: 567-72.
87. Rang HP, Dale MM, Ritter JM, Flower RJ. How drugs act: general principles. In: Rang & Dale's Pharmacology 6 ed. Philidelphia, Churchill Livingstone Elsevier 2007; 8-23.
88. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
89. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276: 12856-63.
90. LoVerme J, Russo R, La Rana G, Vu J, Farthing J, Mattace-Raso G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-α. J Pharmacol Exp Ther 2006; 319: 1051-61.
91. Nilsson O, Fowler CJ, Jacobsson SOP. The cannabinoid agonist WIN 55,212-2 inhibits TNF-α-induced neutrophil transmigration across ECV304 cells. Eur J Pharmacol 2006; 547: 165-73.
92. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15: 598-611.
93. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320:1-13.
94. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 2007; 72: 1393-401.
95. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International union of pharmacology committee on receptor nomenclature and drug classification. XXXVHI. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003; 55: 597-606.
96. 1 receptor-mediated signal transduction. Br J Pharmacol 2004; 142: 1209-18.
97. 1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 2007; 581: 19-29.
98. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 1999; 288: 478-83.
99. Paton WDM. Pharmacology of Marijuana. Ann Rev Pharmacol 1975; 15: 191-220.
100. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 2004; 25: 325-30.
101. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999; 73:2447-59.
102. Wu D-F, Yang L-Q, Goschke A, Stumm R, Brandenburg L-O, Liang Y-J, et al. Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J Neurochem 2008; 104: 1132-43.
103. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2008; 324: 664-73 .
104. Rigamonti AE, Giordani C, Bonomo SM, Cella SG, Müller EE. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 2006; 542: 116-20.
105. Paquette JJ, Wang H-Y, Bakshi K, Olmstead MC. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Behav Pharmacol 2007; 18: 767-76.
106. Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988; 256: 357-61.
107. Lookene A, Skottova N, Olivecrona G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur J Biochem 1994; 222: 395-403.
108. Szabo B, Urbanski MJ, Bisogno T, Di Marzo V, Mendiguren A, Baer WU, et al. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoyl-glycerol. J Physiol 2006; 577: 263-80.
109. 1 receptor activity in rat brain cryosections by functional autoradiography. J Neurochem 2007; 101: 972-81.
110. Hashimotodani Y, Ohno-Shosaku T, Maejima T, Fukami K, Kano M, Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. Neuropharmacology 2008; 54: 58-67.
111. Saario SM, Laitinen JT. Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers 2007; 4: 1903-13.
112. Fowler CJ. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 2006; 20: 549-62.
113. Fowler CJ, Holt S, Nilsson O, Jonsson K-O, Tiger G, Jacobsson SOP. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 2005; 81: 248-62.
114. Högestätt ED, Jönsson BAG, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005; 280: 31405-12.
115. Zygmunt PM, Chuang H-h, Movahed P, Julius D, Högestätt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 2000; 396: 39-42.
116. Khanolkar M, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 1996; 39: 4515-9.
117. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, et al. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 1999; 42: 896-902.
118. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 2004; 101: 8756-61.
119. Vandevoorde S, Fowler CJ. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol 2005; 145: 885-93.
120. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 2000; 11:1231-5.
121. Bari M, Spagnuolo P, Fezza F, Oddi S, Pasquariello N, Finazzi-Agrò A, et al. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. J Immunol 2006; 177:4971-80.
122. Ronesi J, Gerdeman GL, Lovinger DM. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 2004; 24: 1673-9.
123. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006; 281: 36569-78.
124. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004; 311: 441-8.
125. Clapper JR, Duranti A, Tontini A, Mor Tarzia G, Piomelli D. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues.Pharmacol Res 2006; 54: 341-4.
126. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 2007; 52: 1095-105.
127. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007; 46: 13019-30.
128. Niforatos W, Zhang X-F, Lake MR, Walter KA, Neelands T, Holzman TF, et al. Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3′-carbamoylbiphenyl-3-yl cyclohexyl-carbamate (URB597). Mol Pharmacol 2007; 71: 1209-16.
129. Paylor B, Holt S, Fowler CJ. The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res 2006; 54: 481-5. Erratum in: Pharmacol Res 2007; 55: 80.
130. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 1998; 248: 515-22.
131. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007; 150: 766-81.
132. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-12.
133. Vandevoorde S, Jonsson K-O, Labar G, Persson E, Lambert DM, Fowler CJ. Lack of selectivity of URB602 for 2-olcoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 2007; 150: 186-91.
134. Saario SM, Salo OMH, Nevalainen T, Poso A, Laitinen JT, Järvinen T, et al. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 2005; 12: 649-56.
135. Deutsch DG, Omeir F, Arreaza G, Salehani D, Prestwich GD, Huang Z, et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 1997; 53: 255-60.
136. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-24.
137. Craib SJ, Ellington HC, Pertwee RG, Ross RA. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 2001; 13: 30-7.
138. Ho W-SV, Randall MD. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 2007; 150: 641-51.
139. Lebsmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
140. Fowler CJ, Holt S, Tiger G. Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J Enzyme Inhib Med Chem 2003; 18: 55-8.
141. Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundström A, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol 2007; 565: 26-36.
142. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 2004; 24: 10707-15.
143. Safo PK, Regehr WG. Endocannabinoids control the induction of cerebellar LTD. Neuron 2005; 48: 647-59.
144. Vandevoorde S. Overview of the chemical families of faty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008; 8: 247-67.
145. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
146. Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenam-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 2005; 146: 467-76.
147. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006; 147: 281-8.
148. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-5.
149. Trezza V, Vanderschuren LJMJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl) 2008; 197: 217-27.
150. Degn M, Lambertsen KL, Petersen G, Meldgaard M, Artmann A, Clausen BH, et al. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 2007; 103: 1907-16.
151. Nucci C, Gasperi V, Tartaglione R, Cerulli A, Terrinoni A, Bari M, et al. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci 2007; 48: 2997-3004.
152. Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, et al. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 2007; 32: 117-26.
153. Blednoy YA, Cravatt BF, Boehm SL, Walker D, Harris RA. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 2007; 32: 1570-82.
154. Vinod KY, Sanguino E, Yalamanchili R, Manzanares J, Hungund BL. Manipulation of fatty acid amide hydrolase-functional activity alters sensitivity and dependence to ethanol. J Neurochem 2008; 104: 233-43.
155. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
156. Rakhshan F, Day TA, Blakely RD, Barker EL. Carrier-mediated uptake of the endogenous cannabinoid anandamid in RBL-2H3 cells. J Pharmacol Exp Ther 2000; 292: 960-7.
157. Hillard CJ, Jarrahian A. The movement of N-arachidonoylethanol-amine (anandamide) across cellular membranes. Chem Phys Lipids 2000; 108: 123-34.
158. Thors L, Alajakku K, Fowler CJ, The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol 2007; 150: 951-60.
159. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker EL. A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J Biol Chem 2004; 279: 41991-7.
160. Hillard CJ, Jarrahian A. Accumulation of anandamide: Evidence for
161. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277: 1094-7.
162. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000; 483: 52-6.
163. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 2003; 65: 1473-8.
164. López-Rodríguez ML, Viso A, Urtega-Gutiérrez S, Lastres-Becker I, González S, Fernández-Ruiz J, et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 2001; 44: 4505-8.
165. Bojesen IN, Hansen HS. Membrane transport of anandamide through resealed human red blood cell membranes. Lipid Res 2005; 46: 1652-9.
166. Fowler CJ, Tiger G, Ligresti A, López-Rodríguez ML, Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. Eur J Pharmacol 2004; 492: 1-11.
167. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA, 2003; 100: 4269-74.
168. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 2006; 281: 9066-75.
169. Bojesen IN, Hansen HS. Effect of an unstirred layer on the membrane permeability of anandamide. J Lipid Res 2006; 47: 561-70.
170. Thors L, Fowler CJ. Is there a temperature-dependent uptake of anandamide into cells? Br J Pharmacol 2006; 149: 73-81.
171. Karlsson M, Påhlsson C, Fowler CJ. Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur J Pharm Sci 2004; 22: 181-9.
172. Ortega-Gutiérrez S, Hawkins EG, Viso A, López-Rodríguez ML, Cravatt BF. Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 2004; 43: 8184-90.
173. Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenbarger RA, Hillard CJ, et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001; 276: 6967-73.
174. Day TA, Rakhshan F, Deutsch DG, Barker EL. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 2001; 59: 1369-75.
175. Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G, et al. Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 2004; 380: 265-72.
176. Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, et al. Pharmacological characterization of endo-cannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol 2006; 26: 407-23.
177. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying B-P, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA 2005; 102: 17852-7.
178. Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 2006; 128: 9699-704.
179. Thors L, Eriksson J, Fowler CJ. Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. Br J Pharmacol 2007; 152: 744-50.
180. Hillard CJ, Shi L, Tuniki VR, Falck JR, Campbell WB. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci 2007; 33: 18-24.
181. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321: 370-80.
182. Bari M, Battista N, Fezza F, Finazzi-Agro A, Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem. 2005; 280: 12212-20.
183. Ramakrishnan M, Kenoth R, Kamlekar RK, Chandra MS, Radhakrishnan TP, Swamy MJ. N-Myristoylethanolamine-cholesterol (1:1) complex: first evidence from differential scanning calorimetry, fast-atom-bombardment mass spectrometry and computational modelling. FEBS Lett 2002; 531: 343-7.
184. Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E, et al. Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci 2008; 65: 840-50.
185. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-32.
186. Saario SM, Palomäki V, Lehtonen M, Nevalainen T, Järvinen T, Laitinen JT. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem Biol 2006; 13: 811-4.
187. Tarzia G, Antonietti F, Duranti A, Tontini A, Mor M, Rivara S, et al. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo [d][1,3] oxazin-4-one (URB754). Ann Chim 2007; 97: 887-94.
188. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 2004; 66: 1260-4.
189. Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM, et al. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 2007; 27: 2883-9.
190. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 2007; 14: 1357-65.
191. Labar G, Bauvois C, Muccioli GG, Wouters J, Lambert DM. Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 2007; 8: 1293-7.
192. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 2007; 208: 110-9.
193. Bharatam PV, Patel DS, Adane L, Mittal A, Sundriyal S. Modeling and informatics in designing anti-diabetic agents. Curr Pharm Des 2007; 13(34):3518-30.
194. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008; 14(1): 42-54.
195. Viso A, Cisneros JA, Ortega-Gutierrez S. The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr Top Med Chem 2008; 8(3): 231-46.